

The Cost of Opioid Use Disorder in State Medicaid: *Over \$25 Billion in 2022*



Key Findings



Approximately 42,843 patients who were newly diagnosed with OUD in 2022 in the fee-for-service Medicaid population.



Medicaid patients newly diagnosed with OUD in 2022 incurred nearly **\$14,000 more** in health care costs than their non-OUD counterparts.



Higher costs were seen across all care settings. This translates to **~\$600M in additional Medicaid spending**.



Applied across the 1.8M beneficiaries diagnosed with OUD, this totals **\$25.2 billion in 2022**.

Additional Insights



Inpatient: Almost **5x** higher
(\$2,732 vs. \$11,447)



Physician/Outpatient:
Nearly **50%** higher
(\$8,186 vs. \$12,145)



Pharmacy: Over **35%** higher
(\$3,724 vs. \$5,093)

VOICES
FOR NON-OPIOID
CHOICES

www.nonopioidchoices.org

The Moran Company, a Health Management Associates Company's analysis was a targeted state-by-state breakdowns of OUD's fiscal impact on Medicaid to date. **The findings give an economic point to a human loss, highlighting the urgent need for upstream solutions that prevent opioid addiction before it begins.**

The Moran Company, a Health Management Associates Company, "Opioid Use Disorder in the Medicaid Fee-for-Service Program Economic Analysis". July 2025.
<https://www.healthmanagement.com/wp-content/uploads/Opioid-Use-Disorder-Economic-Impact-on-Medicaid-Program-073125.pdf>.